ASMB•benzinga•
Assembly Biosciences Doses First Participant In Phase 1a Clinical Study Of Oral Entry Inhibitor Candidate ABI-6250 For Hepatitis Delta Virus; Phase 1a Study Will Evaluate Single And Multiple Ascending Doses Of ABI-6250 In Healthy Participants With Data E
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga